# Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Study · id `cardio:ct-nct05140694` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05140694](<https://clinicaltrials.gov/study/NCT05140694>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05140694

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 135 participants.

## Technical summary

Registry record NCT05140694. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (anticipated); primary completion 2024-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 135 participants (planned count; ClinicalTrials.gov record NCT05140694, source copy `cardio:ctgov-nct05140694-2022-10-04`, retrieved 2026-10-26)
- Planned start: 2023-12-01 (anticipated) (ClinicalTrials.gov record NCT05140694, source copy `cardio:ctgov-nct05140694-2022-10-04`, retrieved 2026-10-26)
- Primary completion: 2024-06-30 (anticipated) (ClinicalTrials.gov record NCT05140694, source copy `cardio:ctgov-nct05140694-2022-10-04`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT05140694, source copy `cardio:ctgov-nct05140694-2022-10-04`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05140694-2022-10-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Condition: Metabolic-associated Fatty Liver Disease
- Condition: Type 2 Diabetes
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Empagliflozin and Dulaglutide
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)

## Provenance

Content hash: 32c9d82832e2fe03d9658c5419a922efe920faea3600e67bfe5d1a59239ab8e1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
